Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
07 2021
Historique:
received: 30 07 2020
accepted: 30 12 2020
revised: 20 12 2020
pubmed: 4 2 2021
medline: 5 3 2022
entrez: 3 2 2021
Statut: ppublish

Résumé

Cancer stem cells (CSCs) are tumor subpopulations driving disease development, progression, relapse and therapy resistance, and their targeting ensures tumor eradication. CSCs display heterogeneous replication stress (RS), but the functionality/relevance of the RS response (RSR) centered on the ATR-CHK1 axis is debated. Here, we show that the RSR is efficient in primary CSCs from colorectal cancer (CRC-SCs), and describe unique roles for PARP1 and MRE11/RAD51. First, we demonstrated that PARP1 is upregulated in CRC-SCs resistant to several replication poisons and RSR inhibitors (RSRi). In these cells, PARP1 modulates replication fork speed resulting in low constitutive RS. Second, we showed that MRE11 and RAD51 cooperate in the genoprotection and mitosis execution of PARP1-upregulated CRC-SCs. These roles represent therapeutic vulnerabilities for CSCs. Indeed, PARP1i sensitized CRC-SCs to ATRi/CHK1i, inducing replication catastrophe, and prevented the development of resistance to CHK1i. Also, MRE11i + RAD51i selectively killed PARP1-upregulated CRC-SCs via mitotic catastrophe. These results provide the rationale for biomarker-driven clinical trials in CRC using distinct RSRi combinations.

Identifiants

pubmed: 33531658
doi: 10.1038/s41418-020-00733-4
pii: 10.1038/s41418-020-00733-4
pmc: PMC8257675
doi:

Substances chimiques

Antineoplastic Agents 0
MRE11 protein, human 0
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30
RAD51 protein, human EC 2.7.7.-
Rad51 Recombinase EC 2.7.7.-
MRE11 Homologue Protein EC 3.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2060-2082

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : Start-Up 2016 #18418
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG 2017 grant number 20417
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RF_GR-2013-02357273
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : RF_RF-2016-02362022
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : Grant number RF_GR-2011-02351355

Commentaires et corrections

Type : CommentIn

Références

Hinohara K, Polyak K. Intratumoral heterogeneity: more than just mutations. Trends Cell Biol. 2019;29:569–79. https://doi.org/10.1016/j.tcb.2019.03.003 .
doi: 10.1016/j.tcb.2019.03.003 pubmed: 30987806 pmcid: 6579620
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94. https://doi.org/10.1038/nrclinonc.2017.166 .
doi: 10.1038/nrclinonc.2017.166 pubmed: 29115304
Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–34. https://doi.org/10.1038/nm.4409 .
doi: 10.1038/nm.4409 pubmed: 28985214
Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11:47–76. https://doi.org/10.1146/annurev-pathol-012615-044438 .
doi: 10.1146/annurev-pathol-012615-044438 pubmed: 27193450
Roerink SF, Sasaki N, Lee-Six H, Young MD, Alexandrov LB, Behjati S, et al. Intra-tumour diversification in colorectal cancer at the single-cell level. Nature. 2018;556:457–62. https://doi.org/10.1038/s41586-018-0024-3 .
doi: 10.1038/s41586-018-0024-3 pubmed: 29643510
Cortina C, Turon G, Stork D, Hernando-Momblona X, Sevillano M, Aguilera M, et al. A genome editing approach to study cancer stem cells in human tumors. EMBO Mol Med. 2017;9:869–79. https://doi.org/10.15252/emmm.201707550 .
doi: 10.15252/emmm.201707550 pubmed: 28468934 pmcid: 5494503
de Sousa e Melo F, Kurtova AV, Harnoss JM, Kljavin N, Hoeck JD, Hung J, et al. A distinct role for Lgr5(+) stem cells in primary and metastatic colon cancer. Nature. 2017;543:676–80. https://doi.org/10.1038/nature21713 .
doi: 10.1038/nature21713 pubmed: 28358093
Shimokawa M, Ohta Y, Nishikori S, Matano M, Takano A, Fujii M, et al. Visualization and targeting of LGR5(+) human colon cancer stem cells. Nature. 2017;545:187–92. https://doi.org/10.1038/nature22081 .
doi: 10.1038/nature22081 pubmed: 28355176
Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14:342–56. https://doi.org/10.1016/j.stem.2014.01.009 .
doi: 10.1016/j.stem.2014.01.009 pubmed: 24607406
Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science. 2012;337:730–5. https://doi.org/10.1126/science.1224676 .
doi: 10.1126/science.1224676 pubmed: 22855427
Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA, et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol. 2011;29:1120–7. https://doi.org/10.1038/nbt.2038 .
doi: 10.1038/nbt.2038 pubmed: 22081019 pmcid: 3237928
O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106–10. https://doi.org/10.1038/nature05372 .
doi: 10.1038/nature05372 pubmed: 17122772
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5. https://doi.org/10.1038/nature05384 .
doi: 10.1038/nature05384 pubmed: 17122771
Lytle NK, Barber AG, Reya T. Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer. 2018;18:669–80. https://doi.org/10.1038/s41568-018-0056-x .
doi: 10.1038/s41568-018-0056-x pubmed: 30228301 pmcid: 8388042
Quintanal-Villalonga A, Chan JM, Yu HA, Pe’er D, Sawyers CL, Sen T, et al. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020, https://doi.org/10.1038/s41571-020-0340-z .
de Sousa EMF, de Sauvage FJ. Cellular plasticity in intestinal homeostasis and disease. Cell Stem Cell. 2019;24:54–64. https://doi.org/10.1016/j.stem.2018.11.019 .
doi: 10.1016/j.stem.2018.11.019
Prager BC, Xie Q, Bao S, Rich JN. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell. 2019;24:41–53. https://doi.org/10.1016/j.stem.2018.12.009 .
doi: 10.1016/j.stem.2018.12.009 pubmed: 30609398 pmcid: 6350931
Dieter SM, Ball CR, Hoffmann CM, Nowrouzi A, Herbst F, Zavidij O, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell. 2011;9:357–65. https://doi.org/10.1016/j.stem.2011.08.010 .
doi: 10.1016/j.stem.2011.08.010 pubmed: 21982235
Giessler KM, Kleinheinz K, Huebschmann D, Balasubramanian GP, Dubash TD, Dieter SM, et al. Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J Exp Med. 2017;214:2073–88. https://doi.org/10.1084/jem.20162017 .
doi: 10.1084/jem.20162017 pubmed: 28572216 pmcid: 5502434
Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, Brown AM, et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013;339:543–8. https://doi.org/10.1126/science.1227670 .
doi: 10.1126/science.1227670 pubmed: 23239622
Manic G, Signore M, Sistigu A, Russo G, Corradi F, Siteni S, et al. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. Gut. 2018;67:903–17. https://doi.org/10.1136/gutjnl-2016-312623 .
doi: 10.1136/gutjnl-2016-312623 pubmed: 28389531
Pang R, Law WL, Chu AC, Poon JT, Lam CS, Chow AK, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell. 2010;6:603–15. https://doi.org/10.1016/j.stem.2010.04.001 .
doi: 10.1016/j.stem.2010.04.001 pubmed: 20569697
Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell. 2014;15:692–705. https://doi.org/10.1016/j.stem.2014.11.012 .
doi: 10.1016/j.stem.2014.11.012 pubmed: 25479747
Bhaduri A, Di Lullo E, Jung D, Muller S, Crouch EE, Espinosa CS, et al. Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma. Cell Stem Cell. 2020;26:48–63 e46. https://doi.org/10.1016/j.stem.2019.11.015 .
doi: 10.1016/j.stem.2019.11.015 pubmed: 31901251 pmcid: 7029801
Vitale I, Manic G, De Maria R, Kroemer G, Galluzzi L. DNA damage in stem cells. Mol Cell. 2017;66:306–19. https://doi.org/10.1016/j.molcel.2017.04.006 .
doi: 10.1016/j.molcel.2017.04.006 pubmed: 28475867
Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019;19:97–109. https://doi.org/10.1038/s41568-018-0095-3 .
doi: 10.1038/s41568-018-0095-3 pubmed: 30578414 pmcid: 6493335
Manic G, Sistigu A, Corradi F, Musella M, De Maria R, Vitale I. Replication stress response in cancer stem cells as a target for chemotherapy. Semin Cancer Biol. 2018;53:31–41. https://doi.org/10.1016/j.semcancer.2018.08.003 .
doi: 10.1016/j.semcancer.2018.08.003 pubmed: 30081229
Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18:622–36. https://doi.org/10.1038/nrm.2017.67 .
doi: 10.1038/nrm.2017.67 pubmed: 28811666 pmcid: 5796526
Techer H, Koundrioukoff S, Nicolas A, Debatisse M. The impact of replication stress on replication dynamics and DNA damage in vertebrate cells. Nat Rev Genet. 2017;18:535–50. https://doi.org/10.1038/nrg.2017.46 .
doi: 10.1038/nrg.2017.46 pubmed: 28714480
Vesela E, Chroma K, Turi Z, Mistrik M. Common chemical inductors of replication stress: focus on cell-based studies. Biomolecules. 2017, 7, https://doi.org/10.3390/biom7010019 .
Kotsantis P, Petermann E, Boulton SJ. Mechanisms of oncogene-induced replication stress: jigsaw falling into place. Cancer Disco. 2018;8:537–55. https://doi.org/10.1158/2159-8290.CD-17-1461 .
doi: 10.1158/2159-8290.CD-17-1461
Zeman MK, Cimprich KA. Causes and consequences of replication stress. Nat Cell Biol. 2014;16:2–9. https://doi.org/10.1038/ncb2897 .
doi: 10.1038/ncb2897 pubmed: 24366029 pmcid: 4354890
Toledo LI, Altmeyer M, Rask MB, Lukas C, Larsen DH, Povlsen LK, et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell. 2013;155:1088–103. https://doi.org/10.1016/j.cell.2013.10.043 .
doi: 10.1016/j.cell.2013.10.043 pubmed: 24267891
Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179–204. https://doi.org/10.1016/j.molcel.2010.09.019 .
doi: 10.1016/j.molcel.2010.09.019 pubmed: 20965415 pmcid: 2988877
Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541. https://doi.org/10.1038/s41418-017-0012-4 .
doi: 10.1038/s41418-017-0012-4 pubmed: 29362479 pmcid: 5864239
Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006;444:638–42. https://doi.org/10.1038/nature05327 .
doi: 10.1038/nature05327 pubmed: 17136094
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature. 2006;444:633–7. https://doi.org/10.1038/nature05268 .
doi: 10.1038/nature05268 pubmed: 17136093
Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70. https://doi.org/10.1038/nature03482 .
doi: 10.1038/nature03482 pubmed: 15829956
Gaillard H, Garcia-Muse T, Aguilera A. Replication stress and cancer. Nat Rev Cancer. 2015;15:276–89. https://doi.org/10.1038/nrc3916 .
doi: 10.1038/nrc3916 pubmed: 25907220
Burrell RA, McClelland SE, Endesfelder D, Groth P, Weller MC, Shaikh N, et al. Replication stress links structural and numerical cancer chromosomal instability. Nature. 2013;494:492–6. https://doi.org/10.1038/nature11935 .
doi: 10.1038/nature11935 pubmed: 23446422 pmcid: 4636055
Carruthers RD, Ahmed SU, Ramachandran S, Strathdee K, Kurian KM, Hedley A, et al. Replication stress drives constitutive activation of the DNA damage response and radioresistance in glioblastoma stem-like cells. Cancer Res. 2018;78:5060–71. https://doi.org/10.1158/0008-5472.CAN-18-0569 .
doi: 10.1158/0008-5472.CAN-18-0569 pubmed: 29976574 pmcid: 6128404
McGrail DJ, Lin CC, Dai H, Mo W, Li Y, Stephan C, et al. Defective replication stress response is inherently linked to the cancer stem cell phenotype. Cell Rep. 2018;23:2095–106. https://doi.org/10.1016/j.celrep.2018.04.068 .
doi: 10.1016/j.celrep.2018.04.068 pubmed: 29768207
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Disco. 2018;8:1404–21. https://doi.org/10.1158/2159-8290.CD-18-0474 .
doi: 10.1158/2159-8290.CD-18-0474
Ercilla A, Llopis A, Feu S, Aranda S, Ernfors P, Freire R, et al. New origin firing is inhibited by APC/CCdh1 activation in S-phase after severe replication stress. Nucleic Acids Res. 2016;44:4745–62. https://doi.org/10.1093/nar/gkw132 .
doi: 10.1093/nar/gkw132 pubmed: 26939887 pmcid: 4889930
Mordes DA, Glick GG, Zhao R, Cortez D. TopBP1 activates ATR through ATRIP and a PIKK regulatory domain. Genes Dev. 2008;22:1478–89. https://doi.org/10.1101/gad.1666208 .
doi: 10.1101/gad.1666208 pubmed: 18519640 pmcid: 2418584
Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017;18:610–21. https://doi.org/10.1038/nrm.2017.53 .
doi: 10.1038/nrm.2017.53 pubmed: 28676700 pmcid: 6591728
Quinet A, Carvajal-Maldonado D, Lemacon D, Vindigni A. DNA fiber analysis: mind the gap! Methods Enzymol. 2017;591:55–82. https://doi.org/10.1016/bs.mie.2017.03.019 .
doi: 10.1016/bs.mie.2017.03.019 pubmed: 28645379
Neelsen KJ, Lopes M. Replication fork reversal in eukaryotes: from dead end to dynamic response. Nat Rev Mol Cell Biol. 2015;16:207–20. https://doi.org/10.1038/nrm3935 .
doi: 10.1038/nrm3935 pubmed: 25714681
Malacaria E, Pugliese GM, Honda M, Marabitti V, Aiello FA, Spies M, et al. Rad52 prevents excessive replication fork reversal and protects from nascent strand degradation. Nat Commun. 2019;10:1412 https://doi.org/10.1038/s41467-019-09196-9 .
doi: 10.1038/s41467-019-09196-9 pubmed: 30926821 pmcid: 6441034
Pommier Y, O’Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016, 8, 362ps317, https://doi.org/10.1126/scitranslmed.aaf9246 .
Zandarashvili L, Langelier MF, Velagapudi UK, Hancock MA, Steffen JD, Billur R, et al. Structural basis for allosteric PARP-1 retention on DNA breaks. Science. 2020, 368, https://doi.org/10.1126/science.aax6367 .
Rickman K, Smogorzewska A. Advances in understanding DNA processing and protection at stalled replication forks. J Cell Biol. 2019;218:1096–107. https://doi.org/10.1083/jcb.201809012 .
doi: 10.1083/jcb.201809012 pubmed: 30670471 pmcid: 6446843
Manic G, Corradi F, Sistigu A, Siteni S, Vitale I. Molecular regulation of the spindle assembly checkpoint by kinases and phosphatases. Int Rev Cell Mol Biol. 2017;328:105–61. https://doi.org/10.1016/bs.ircmb.2016.08.004 .
doi: 10.1016/bs.ircmb.2016.08.004 pubmed: 28069132
Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;12:385–92. https://doi.org/10.1038/nrm3115 .
doi: 10.1038/nrm3115 pubmed: 21527953
Berti M, Ray Chaudhuri A, Thangavel S, Gomathinayagam S, Kenig S, Vujanovic M, et al. Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition. Nat Struct Mol Biol. 2013;20:347–54. https://doi.org/10.1038/nsmb.2501 .
doi: 10.1038/nsmb.2501 pubmed: 23396353 pmcid: 3897332
Ray Chaudhuri A, Hashimoto Y, Herrador R, Neelsen KJ, Fachinetti D, Bermejo R, et al. Topoisomerase I poisoning results in PARP-mediated replication fork reversal. Nat Struct Mol Biol. 2012;19:417–23. https://doi.org/10.1038/nsmb.2258 .
doi: 10.1038/nsmb.2258 pubmed: 22388737
Zellweger R, Dalcher D, Mutreja K, Berti M, Schmid JA, Herrador R, et al. Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells. J Cell Biol. 2015;208:563–79. https://doi.org/10.1083/jcb.201406099 .
doi: 10.1083/jcb.201406099 pubmed: 25733714 pmcid: 4347635
Mutreja K, Krietsch J, Hess J, Ursich S, Berti M, Roessler FK, et al. ATR-mediated global fork slowing and reversal assist fork traverse and prevent chromosomal breakage at DNA interstrand cross-links. Cell Rep. 2018;24:2629–42 e2625. https://doi.org/10.1016/j.celrep.2018.08.019 .
doi: 10.1016/j.celrep.2018.08.019 pubmed: 30184498 pmcid: 6137818
Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535:382–7. https://doi.org/10.1038/nature18325 .
doi: 10.1038/nature18325 pubmed: 27443740
Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J. High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018;559:279–84. https://doi.org/10.1038/s41586-018-0261-5 .
doi: 10.1038/s41586-018-0261-5 pubmed: 29950726
Hanzlikova H, Kalasova I, Demin AA, Pennicott LE, Cihlarova Z, Caldecott KW. The importance of poly(ADP-Ribose) polymerase as a sensor of unligated Okazaki fragments during DNA replication. Mol Cell. 2018;71:319–331 e313. https://doi.org/10.1016/j.molcel.2018.06.004 .
doi: 10.1016/j.molcel.2018.06.004 pubmed: 29983321 pmcid: 6060609
Bajaj J, Diaz E, Reya T. Stem cells in cancer initiation and progression. J Cell Biol. 2020, 219, https://doi.org/10.1083/jcb.201911053 .
Mijic S, Zellweger R, Chappidi N, Berti M, Jacobs K, Mutreja K, et al. Replication fork reversal triggers fork degradation in BRCA2-defective cells. Nat Commun. 2017;8:859 https://doi.org/10.1038/s41467-017-01164-5 .
doi: 10.1038/s41467-017-01164-5 pubmed: 29038466 pmcid: 5643541
Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell. 2011;145:529–42. https://doi.org/10.1016/j.cell.2011.03.041 .
doi: 10.1016/j.cell.2011.03.041 pubmed: 21565612 pmcid: 3261725
Hashimoto Y, Ray Chaudhuri A, Lopes M, Costanzo V. Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis. Nat Struct Mol Biol. 2010;17:1305–11. https://doi.org/10.1038/nsmb.1927 .
doi: 10.1038/nsmb.1927 pubmed: 20935632 pmcid: 4306207
Mason JM, Chan YL, Weichselbaum RW, Bishop DK. Non-enzymatic roles of human RAD51 at stalled replication forks. Nat Commun. 2019;10:4410 https://doi.org/10.1038/s41467-019-12297-0 .
doi: 10.1038/s41467-019-12297-0 pubmed: 31562309 pmcid: 6764946
Lemacon D, Jackson J, Quinet A, Brickner JR, Li S, Yazinski S, et al. MRE11 and EXO1 nucleases degrade reversed forks and elicit MUS81-dependent fork rescue in BRCA2-deficient cells. Nat Commun. 2017;8:860 https://doi.org/10.1038/s41467-017-01180-5 .
doi: 10.1038/s41467-017-01180-5 pubmed: 29038425 pmcid: 5643552
Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, et al. T. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 2009;28:2601–15. https://doi.org/10.1038/emboj.2009.206 .
doi: 10.1038/emboj.2009.206 pubmed: 19629035 pmcid: 2738702
Xu R, Xu Y, Huo W, Lv Z, Yuan J, Ning S, et al. Mitosis-specific MRN complex promotes a mitotic signaling cascade to regulate spindle dynamics and chromosome segregation. Proc Natl Acad Sci USA. 2018;115:E10079–E10088. https://doi.org/10.1073/pnas.1806665115 .
doi: 10.1073/pnas.1806665115 pubmed: 30297404 pmcid: 6205471
Syed A, Tainer JA. The MRE11-RAD50-NBS1 complex conducts the orchestration of damage signaling and outcomes to stress in DNA replication and repair. Annu Rev Biochem. 2018;87:263–94. https://doi.org/10.1146/annurev-biochem-062917-012415 .
doi: 10.1146/annurev-biochem-062917-012415 pubmed: 29709199 pmcid: 6076887
Rozier L, Guo Y, Peterson S, Sato M, Baer R, Gautier J, et al. The MRN-CtIP pathway is required for metaphase chromosome alignment. Mol Cell. 2013;49:1097–107. https://doi.org/10.1016/j.molcel.2013.01.023 .
doi: 10.1016/j.molcel.2013.01.023 pubmed: 23434370 pmcid: 3615147
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5. https://doi.org/10.1038/nature07935 .
doi: 10.1038/nature07935 pubmed: 19329995
De Angelis ML, Zeuner A, Policicchio E, Russo G, Bruselles A, Signore M, et al. Cancer stem cell-based models of colorectal cancer reveal molecular determinants of therapy resistance. Stem Cells Transl Med. 2016;5:511–23. https://doi.org/10.5966/sctm.2015-0214 .
doi: 10.5966/sctm.2015-0214 pubmed: 26956206 pmcid: 4798739
Di Veroli GY, Fornari C, Wang D, Mollard S, Bramhall JL, Richards FM, et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics. 2016;32:2866–8. https://doi.org/10.1093/bioinformatics/btw230 .
doi: 10.1093/bioinformatics/btw230 pubmed: 27153664 pmcid: 5018366
Zagidullin B, Aldahdooh J, Zheng S, Wang W, Wang Y, Saad J, et al. DrugComb: an integrative cancer drug combination data portal. Nucleic Acids Res. 2019;47:W43–W51. https://doi.org/10.1093/nar/gkz337 .
doi: 10.1093/nar/gkz337 pubmed: 31066443 pmcid: 6602441
Vitale I, Jemaa M, Galluzzi L, Metivier D, Castedo M, Kroemer G. Cytofluorometric assessment of cell cycle progression. Methods Mol Biol. 2013;965:93–120. https://doi.org/10.1007/978-1-62703-239-1_6 .
doi: 10.1007/978-1-62703-239-1_6 pubmed: 23296653
Liu Y, Bertram CC, Shi Q, Zinkel SS. Proapoptotic Bid mediates the Atr-directed DNA damage response to replicative stress. Cell Death Differ. 2011;18:841–52. https://doi.org/10.1038/cdd.2010.151 .
doi: 10.1038/cdd.2010.151 pubmed: 21113148
Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164 https://doi.org/10.1093/nar/gkq603 .
doi: 10.1093/nar/gkq603 pubmed: 20601685 pmcid: 2938201
Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062–D1067. https://doi.org/10.1093/nar/gkx1153 .
doi: 10.1093/nar/gkx1153 pubmed: 29165669
Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14:e1007752 https://doi.org/10.1371/journal.pgen.1007752 .
doi: 10.1371/journal.pgen.1007752 pubmed: 30586411 pmcid: 6324924
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017, 2017, https://doi.org/10.1200/PO.17.00011 .

Auteurs

Gwenola Manic (G)

IIGM - Italian Institute for Genomic Medicine, c/o IRCSS, Candiolo, Italy. gwenola.manic@gmail.com.
Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Italy. gwenola.manic@gmail.com.

Martina Musella (M)

Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Francesca Corradi (F)

Department of Biology, University of Rome "Tor Vergata", Rome, Italy.

Antonella Sistigu (A)

Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
UOSD Immunology and Immunotherapy Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Sara Vitale (S)

Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Sara Soliman Abdel Rehim (S)

IIGM - Italian Institute for Genomic Medicine, c/o IRCSS, Candiolo, Italy.
Department of Biology, University of Rome "Tor Vergata", Rome, Italy.

Luca Mattiello (L)

IIGM - Italian Institute for Genomic Medicine, c/o IRCSS, Candiolo, Italy.
Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Italy.

Eva Malacaria (E)

Mechanisms, Biomarkers and Models Unit, Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.

Claudia Galassi (C)

Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.

Michele Signore (M)

RPPA unit, Proteomics area, Core Facilities, Istituto Superiore di Sanità, Rome, Italy.

Matteo Pallocca (M)

UOSD Biostatistics, Bioinformatics and Clinical Trial Center, IRCSS Regina Elena National Cancer Institute, Rome, Italy.

Stefano Scalera (S)

UOSD SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Frauke Goeman (F)

Oncogenomic and Epigenetic Unit, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Francesca De Nicola (F)

UOSD SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Andrea Guarracino (A)

IIGM - Italian Institute for Genomic Medicine, c/o IRCSS, Candiolo, Italy.
Department of Biology, University of Rome "Tor Vergata", Rome, Italy.

Rosa Pennisi (R)

Department of Experimental Oncology, European Institute of Oncology (IEO), Milano, Italy.

Fabrizio Antonangeli (F)

Department of Molecular Medicine, University "La Sapienza", Laboratory affiliated to Istituto Pasteur Italia, Rome, Italy.
Institute of Molecular Biology and Pathology, National Research Council (CNR), Rome, Italy.

Francesca Sperati (F)

UOSD Biostatistics, Bioinformatics and Clinical Trial Center, San Gallicano Dermatological Institute IRCCS, Rome, Italy.

Marta Baiocchi (M)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Mauro Biffoni (M)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.

Maurizio Fanciulli (M)

UOSD SAFU, Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Marcello Maugeri-Saccà (M)

Division of Medical Oncology 2, IRCSS Regina Elena National Cancer Institute, Rome, Italy.

Annapaola Franchitto (A)

Mechanisms, Biomarkers and Models Unit, Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.

Pietro Pichierri (P)

Mechanisms, Biomarkers and Models Unit, Department of Environment and Health, Istituto Superiore di Sanità, Rome, Italy.

Ruggero De Maria (R)

Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy. ruggero.demaria@unicatt.it.
Fondazione Policlinico Universitario "A. Gemelli" - IRCCS, Rome, Italy. ruggero.demaria@unicatt.it.

Ilio Vitale (I)

IIGM - Italian Institute for Genomic Medicine, c/o IRCSS, Candiolo, Italy. iliovit@gmail.com.
Candiolo Cancer Institute, FPO - IRCCS, Candiolo, Italy. iliovit@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH